Berg, G., Barchuk, M., Lobo, M
In the SELECT CV outcome trial, which included patients aged 45 years or older with a body mass index (BMI) 27.0 kg m 2 and established ASCVD but without diabetes, those treated with the glucagon-like peptide-1 receptor agonist (GLP-1RA), semaglutide 2.4 mg, had a 20% MACE reduction compared with those receiving placebo on top of standard of care 12
This time it's kind of a sad one rather than a fun one
During the peer review process, Orphan EuropeRecordati Group, the marketing-authorization holder of carglumic acid, was also offered an opportunity to provide a scientific accuracy review of their data
All of these hormones are released after food intake and complement the effect of semaglutide in suppressing appetite and maintaining blood sugar levels
Acute illness may require temporary dose adjustment or suspension of GLP-1 therapy, particularly if you cannot maintain adequate fluid intake